Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis

• Published in: Clinical ophthalmology (Auckland, N.Z.) N.Z.), 2021, Vol.15, p.253-260
• Main Authors: Pessoa, Bernardete, Malheiro, Luísa, Carneiro, Inês, Monteiro, Sílvia, Coelho, João, Coelho, Constança, Figueira, João, Meireles, Angelina, Melo Beirão, João Nuno
• Format: Article
• Language: English
• Subjects: Aflibercept; Bevacizumab; Diabetic macular edema; Ranibizumab; Refractory
• ISSN: 1177-5483
• DOI: 10.2147/OPTH.S280644

© 2021 Pessoa et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab. Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed prior to and 4 months after the switch. Ocular coherence tomography (OCT) biomarkers were also analysed. Results: Fifty-six eyes from 40 patients were included in the study, 33 eyes switched to ranibizumab and 23 to aflibercept. A significant median CFT decrease was observed in both groups (p